Last reviewed · How we verify
SARS-CoV-2 Vaccine
SARS-CoV-2 Vaccine is a vaccine Biologic drug developed by Hospitales Universitarios Virgen del Rocío. It is currently in Phase 3 development for Prevention of COVID-19 infection and severe disease. Also known as: mRNA-1273.
This vaccine trains the immune system to recognize and attack SARS-CoV-2 virus by presenting viral antigens or genetic instructions to produce them.
This vaccine trains the immune system to recognize and attack SARS-CoV-2 virus by presenting viral antigens or genetic instructions to produce them. Used for Prevention of COVID-19 infection and severe disease.
At a glance
| Generic name | SARS-CoV-2 Vaccine |
|---|---|
| Also known as | mRNA-1273 |
| Sponsor | Hospitales Universitarios Virgen del Rocío |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
SARS-CoV-2 vaccines work by stimulating both humoral (antibody) and cellular (T-cell) immune responses against the virus. Depending on the platform (mRNA, viral vector, protein subunit, or inactivated virus), the vaccine either delivers genetic material encoding the spike protein or the protein itself, enabling the body to mount a protective immune response before natural infection occurs.
Approved indications
- Prevention of COVID-19 infection and severe disease
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 Vaccine CI brief — competitive landscape report
- SARS-CoV-2 Vaccine updates RSS · CI watch RSS
- Hospitales Universitarios Virgen del Rocío portfolio CI
Frequently asked questions about SARS-CoV-2 Vaccine
What is SARS-CoV-2 Vaccine?
How does SARS-CoV-2 Vaccine work?
What is SARS-CoV-2 Vaccine used for?
Who makes SARS-CoV-2 Vaccine?
Is SARS-CoV-2 Vaccine also known as anything else?
What drug class is SARS-CoV-2 Vaccine in?
What development phase is SARS-CoV-2 Vaccine in?
What are the side effects of SARS-CoV-2 Vaccine?
What does SARS-CoV-2 Vaccine target?
Related
- Drug class: All vaccine drugs
- Target: All drugs targeting SARS-CoV-2 spike protein
- Manufacturer: Hospitales Universitarios Virgen del Rocío — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of COVID-19 infection and severe disease
- Also known as: mRNA-1273
- Compare: SARS-CoV-2 Vaccine vs similar drugs
- Pricing: SARS-CoV-2 Vaccine cost, discount & access